




The relative strengths and weaknesses of Lumos Pharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lumos Pharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 109% points. The greatest weakness of Lumos Pharma INC is the variable Research and Development, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 348%, being 99% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	127,072
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,847
Liabilities, Non-Current	6,949
Other Assets	140
Other Compr. Net Income	0
Other Expenses	-6,968
Other Liabilities	0
Other Net Income	1,875
Other Revenues	12,474
Property and Equipment	3,727
Research and Development	45,694
Selling, General and Administrative Expense	29,218

Output Variable	Value in 1000 USD
Assets	130,939
Liabilities	15,796
Expenses	67,944
Revenues	12,474
Stockholders Equity	115,143
Net Income	-53,595
Comprehensive Net Income	-53,595
BaseVar	114,514
ECR before Limited Liability	269%
Economic Capital Ratio	348%